Fennec Pharmaceuticals INC Form 4 insider transactions

Director Rosty Raykov of Fennec Pharmaceuticals Inc. [FENC] donated a portion of his common shares to charity on August 23, 2024.

Director Khalid Islam of Fennec Pharmaceuticals was granted a non-qualified stock option to purchase 25,000 shares of the company's common stock on August 15, 2024.

Director Jodi Cook was granted stock options to purchase 20,000 shares of Fennec Pharmaceuticals on August 15, 2024.

Marco Maria Brughera, a director of Fennec Pharmaceuticals, was granted a stock option to purchase 20,000 shares of the company's common stock on August 15, 2024.

Director Chris Rallis of Fennec Pharmaceuticals was granted a stock option to purchase 20,000 shares of the company's common stock on August 15, 2024.

Fennec Pharmaceuticals' CEO, Jeffrey S. Hackman, was granted incentive stock options to purchase 400,000 shares of the company's common stock on August 15, 2024.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on July 31, 2024.

Fennec Pharmaceuticals CEO Rostislav Raykov reports the sale of 2,431 common shares at $6.255 per share, pursuant to a pre-arranged 10b5-1 trading plan.

Chris A. Rallis, a director of Fennec Pharmaceuticals, exercised options to acquire 1,792 shares at $2.79 each and sold 1,173 shares at $6.03 to cover tax obligations.

Fennec Pharmaceuticals CEO Rosty Raykov reports the acquisition and disposal of common shares, including shares sold under a 10b5-1 plan.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition and disposal of common shares on July 1, 2024.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on May 31, 2024.

Fennec Pharmaceuticals CEO Rostislav Raykov reports the sale of 2,431 common shares at $6.76 each, executed under a pre-arranged 10b5-1 trading plan.

Adrian Haigh, Chief Operating Officer of Fennec Pharmaceuticals, was granted stock options and restricted share units on May 16, 2024, according to a Form 4 filing.

Fennec Pharmaceuticals' CEO, Rostislav Raykov, was granted stock options and restricted share units on May 16, 2024, according to a recent SEC filing.

Robert Andrade, CFO of Fennec Pharmaceuticals, was granted stock options for 100,000 shares and restricted share units for 50,000 shares on May 16, 2024, according to a Form 4 filing.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on April 30, 2024.

CEO Rosty Raykov reports acquisition and disposal of Fennec Pharmaceuticals shares, including sales under a 10b5-1 plan.

Adrian Haigh, COO of Fennec Pharmaceuticals, files an amended Form 4 to correct the transaction code for common share acquisitions on April 17 and 18, 2024.

Adrian Haigh, COO of Fennec Pharmaceuticals, files an amended Form 4 to correct the transaction code for common shares acquired through option exercises under a 10b5-1 plan.

Adrian Haigh, COO of Fennec Pharmaceuticals, executed option exercises and subsequent share disposals under a pre-arranged 10b5-1 trading plan.

Adrian Haigh, COO of Fennec Pharmaceuticals, reports transactions involving the exercise of options and disposal of common shares under a pre-arranged 10b5-1 trading plan.

Adrian Haigh, COO of Fennec Pharmaceuticals, reports transactions involving common shares and options, including acquisitions and disposals, under a pre-arranged 10b5-1 trading plan.

Director Chris A. Rallis of Fennec Pharmaceuticals reports the sale of 800 common shares and the exercise of options for 1,389 shares on April 15, 2024.

Fennec Pharmaceuticals CEO Rostislav Raykov sold a total of 88,583 common shares between April 4th and April 5th, 2024, under a pre-arranged 10b5-1 trading plan.

Fennec Pharmaceuticals CEO Rosty Raykov sold a total of 40,584 common shares on April 3, 2024, under a pre-arranged 10b5-1 trading plan.

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 12,500 common shares on April 1, 2024, due to the release of restrictions from shares awarded on March 31, 2023.

Fennec Pharmaceuticals CEO Rostislav Raykov reports the release of restriction from 29,167 common shares awarded on March 31, 2023, resulting in a total beneficial ownership of 316,638 shares.

Director Chris A. Rallis of Fennec Pharmaceuticals reports the sale and acquisition of common shares, including transactions related to option exercises and a pre-arranged 10b5-1 trading plan.

Robert Andrade, CFO of Fennec Pharmaceuticals, sold 13,975 common shares at a price of $10.9013 per share on March 26, 2024, under a pre-arranged 10b5-1 trading plan.